DE60306934D1 - Verwendung von Nitrilenverbindungen als Arztneimittel - Google Patents

Verwendung von Nitrilenverbindungen als Arztneimittel

Info

Publication number
DE60306934D1
DE60306934D1 DE60306934T DE60306934T DE60306934D1 DE 60306934 D1 DE60306934 D1 DE 60306934D1 DE 60306934 T DE60306934 T DE 60306934T DE 60306934 T DE60306934 T DE 60306934T DE 60306934 D1 DE60306934 D1 DE 60306934D1
Authority
DE
Germany
Prior art keywords
medicament
nitrile compounds
compounds
diseases associated
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60306934T
Other languages
English (en)
Other versions
DE60306934T2 (de
Inventor
Andrew Bailey
Garry Pairaudeau
Anil Patel
Stephen Thom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60306934D1 publication Critical patent/DE60306934D1/de
Publication of DE60306934T2 publication Critical patent/DE60306934T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE60306934T 2002-06-24 2003-06-23 Verwendung von Nitrilenverbindungen als Arzneimittel Expired - Lifetime DE60306934T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0201977 2002-06-24
SE0201977A SE0201977D0 (sv) 2002-06-24 2002-06-24 Novel compounds
PCT/SE2003/001080 WO2004000825A1 (en) 2002-06-24 2003-06-23 Novel compounds

Publications (2)

Publication Number Publication Date
DE60306934D1 true DE60306934D1 (de) 2006-08-31
DE60306934T2 DE60306934T2 (de) 2007-02-15

Family

ID=20288335

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60306934T Expired - Lifetime DE60306934T2 (de) 2002-06-24 2003-06-23 Verwendung von Nitrilenverbindungen als Arzneimittel

Country Status (12)

Country Link
US (2) US20050245522A1 (de)
EP (1) EP1532124B1 (de)
JP (1) JP2005533805A (de)
AT (1) ATE333451T1 (de)
AU (1) AU2003243097A1 (de)
CY (1) CY1107342T1 (de)
DE (1) DE60306934T2 (de)
DK (1) DK1532124T3 (de)
ES (1) ES2268423T3 (de)
PT (1) PT1532124E (de)
SE (1) SE0201977D0 (de)
WO (1) WO2004000825A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
CN100393700C (zh) * 2003-06-30 2008-06-11 麦克弗罗斯特(加拿大)公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5059786B2 (ja) 2006-02-11 2012-10-31 ジェネトロニクス，インコーポレイティド 単針生体内エレクトロポレーションのための装置および方法
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080200454A1 (en) * 2007-02-15 2008-08-21 Ameriks Michael K Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090118274A1 (en) * 2007-02-15 2009-05-07 Darin Allen Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090099157A1 (en) * 2007-02-15 2009-04-16 Ameriks Michael K Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
BRPI0813306A2 (pt) * 2007-06-26 2017-05-16 Astrazeneca Ab composto, composição farmacêutica, método para produzir a inibição de uma cisteína protease em um mamífero, e, uso de um composto.
WO2009001127A1 (en) * 2007-06-26 2008-12-31 Astrazeneca Ab Cyanocyclopropylcarboxamides as cathepsin inhibitors
WO2009001128A1 (en) * 2007-06-26 2008-12-31 Astrazeneca Ab 1,2-cycl0hexane dicarboxamides as cathepsin inhibitors
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
CH704051B1 (fr) * 2010-11-04 2013-10-15 Nivarox Sa Echappement synchrone pour mécanisme d'horlogerie.
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12882001A3 (sk) * 1999-03-15 2002-04-04 Axys Pharmaceuticals, Inc. Zlúčeniny a prípravky ako proteinázové inhibítory
US6313117B1 (en) * 1999-07-30 2001-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Succinate derivative compounds useful as cysteine protease inhibitors
US20010041700A1 (en) * 1999-07-30 2001-11-15 Younes Bekkali Novel succinate derivative compounds useful as cysteine protease inhibitors
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
DE60306934T2 (de) 2007-02-15
SE0201977D0 (sv) 2002-06-24
ATE333451T1 (de) 2006-08-15
US20080234274A1 (en) 2008-09-25
EP1532124A1 (de) 2005-05-25
EP1532124B1 (de) 2006-07-19
CY1107342T1 (el) 2012-12-19
PT1532124E (pt) 2006-11-30
WO2004000825A1 (en) 2003-12-31
ES2268423T3 (es) 2007-03-16
US20050245522A1 (en) 2005-11-03
AU2003243097A1 (en) 2004-01-06
JP2005533805A (ja) 2005-11-10
DK1532124T3 (da) 2006-10-30

Similar Documents

Publication Publication Date Title
SE0201980D0 (sv) Novel compounds
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
SE0201976D0 (sv) Novel compounds
ATE387197T1 (de) Cyanoalkylamino-derivate als protease-hemmer
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
ATE513917T1 (de) Bakterielle expression von proteaseinhibitoren und varianten davon
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE483692T1 (de) Als beta-sekretase (bace)-hemmer nützliche 2- amino-chinazolinderivate
WO2005028429A3 (en) Haloalkyl containing compounds as cysteine protease inhibitors
DE60310991D1 (de) Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
WO2005074904A3 (en) Silinane compounds as cysteine protease inhibitors
DE60218633D1 (de) Inhibitoren von cruzipain und anderen cysteinproteasen
TW200700057A (en) Alpha ketoamide compounds as cysteine protease inhibitors
TR199902766T2 (xx) Proteaz inhibit�rleri.
DK1539724T3 (da) Aminobenzothiazolforbindelser med NOS-inhiberende aktivitet
SE0203712D0 (sv) Novel compounds
TW200509919A (en) Cathepsin S inhibitors
MX2007011739A (es) Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
WO2005063742A3 (en) Amidino compounds as cysteine protease inhibitors
MX2009003563A (es) Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
WO2002023784A3 (en) Cysteine protease inhibitors
CR6462A (es) Compuestos y composiciones como inhibidores de proteaso

Legal Events

Date Code Title Description
8364 No opposition during term of opposition